Migratory and anti-fibrotic programmes define the regenerative potential of human cardiac progenitors.


Journal

Nature cell biology
ISSN: 1476-4679
Titre abrégé: Nat Cell Biol
Pays: England
ID NLM: 100890575

Informations de publication

Date de publication:
05 2022
Historique:
received: 12 08 2021
accepted: 11 03 2022
pubmed: 14 5 2022
medline: 18 5 2022
entrez: 13 5 2022
Statut: ppublish

Résumé

Heart regeneration is an unmet clinical need, hampered by limited renewal of adult cardiomyocytes and fibrotic scarring. Pluripotent stem cell-based strategies are emerging, but unravelling cellular dynamics of host-graft crosstalk remains elusive. Here, by combining lineage tracing and single-cell transcriptomics in injured non-human primate heart biomimics, we uncover the coordinated action modes of human progenitor-mediated muscle repair. Chemoattraction via CXCL12/CXCR4 directs cellular migration to injury sites. Activated fibroblast repulsion targets fibrosis by SLIT2/ROBO1 guidance in organizing cytoskeletal dynamics. Ultimately, differentiation and electromechanical integration lead to functional restoration of damaged heart muscle. In vivo transplantation into acutely and chronically injured porcine hearts illustrated CXCR4-dependent homing, de novo formation of heart muscle, scar-volume reduction and prevention of heart failure progression. Concurrent endothelial differentiation contributed to graft neovascularization. Our study demonstrates that inherent developmental programmes within cardiac progenitors are sequentially activated in disease, enabling the cells to sense and counteract acute and chronic injury.

Identifiants

pubmed: 35550611
doi: 10.1038/s41556-022-00899-8
pii: 10.1038/s41556-022-00899-8
pmc: PMC9106586
doi:

Substances chimiques

Nerve Tissue Proteins 0
Receptors, Immunologic 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

659-671

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2022. The Author(s).

Références

Cell. 2015 Jun 18;161(7):1566-75
pubmed: 26073943
Cell Stem Cell. 2019 Nov 7;25(5):594-606
pubmed: 31703770
J Neurosci. 2001 Jun 15;21(12):4281-9
pubmed: 11404413
Nat Methods. 2017 Mar;14(3):309-315
pubmed: 28114287
Science. 2011 Feb 25;331(6020):1078-80
pubmed: 21350179
Nat Rev Cardiol. 2017 Aug;14(8):484-491
pubmed: 28436487
Mol Ther. 2018 Jul 5;26(7):1644-1659
pubmed: 29606507
Development. 2011 May;138(9):1663-74
pubmed: 21429987
Dev Cell. 2019 Feb 25;48(4):475-490.e7
pubmed: 30713072
Nature. 2011 Jun 08;474(7353):640-4
pubmed: 21654746
Science. 2018 Mar 9;359(6380):1177-1181
pubmed: 29371425
Stem Cell Reports. 2019 May 14;12(5):967-981
pubmed: 31056479
Proteomics. 2018 Apr;18(7):e1700260
pubmed: 29466620
Methods. 2017 Feb 15;115:80-90
pubmed: 27713081
Nat Commun. 2019 Jan 10;10(1):117
pubmed: 30631059
Nat Med. 2004 Aug;10(8):858-64
pubmed: 15235597
Nature. 2015 Sep 24;525(7570):479-85
pubmed: 26375005
Science. 2017 Jun 9;356(6342):1035-1039
pubmed: 28596337
Glycobiology. 2006 Jun;16(6):488-501
pubmed: 16513763
Nature. 2009 Jul 2;460(7251):113-7
pubmed: 19571884
J Biol Chem. 1998 Sep 4;273(36):23169-75
pubmed: 9722546
Circ Res. 2016 Mar 18;118(6):1021-40
pubmed: 26987915
Circulation. 2017 Aug 15;136(7):680-686
pubmed: 28684531
J Mol Cell Cardiol. 2016 May;94:22-31
pubmed: 26996756
OMICS. 2012 May;16(5):284-7
pubmed: 22455463
Lancet. 2012 Dec 15;380(9859):2095-128
pubmed: 23245604
Stem Cell Res. 2018 Oct;32:65-72
pubmed: 30218895
Circ Res. 2013 Aug 2;113(4):399-407
pubmed: 23743334
Nature. 2017 Jul 13;547(7662):179-184
pubmed: 28581497
Cell Stem Cell. 2019 Apr 4;24(4):506-507
pubmed: 30951657
Front Pharmacol. 2017 Apr 06;8:186
pubmed: 28428753
J Am Coll Cardiol. 2018 Jan 30;71(4):429-438
pubmed: 29389360
Nat Cell Biol. 2013 Sep;15(9):1098-106
pubmed: 23974038
Nat Methods. 2011 Oct 23;8(12):1037-40
pubmed: 22020065
Nat Rev Drug Discov. 2017 Feb;16(2):115-130
pubmed: 27980341
Cell Stem Cell. 2020 Jan 2;26(1):7-16
pubmed: 31901252
Cold Spring Harb Perspect Med. 2013 Oct 01;3(10):a013847
pubmed: 24086063
Cell. 2006 Dec 15;127(6):1151-65
pubmed: 17123592
Nat Protoc. 2007;2(8):1896-906
pubmed: 17703201
J Mol Cell Cardiol. 2008 Oct;45(4):514-22
pubmed: 18304573
Nat Biotechnol. 2019 Mar;37(3):232-237
pubmed: 30778231
Dev Cell. 2019 Mar 25;48(6):765-779.e7
pubmed: 30773489
Nat Biotechnol. 2014 Apr;32(4):381-386
pubmed: 24658644
Nat Cell Biol. 2020 Jan;22(1):108-119
pubmed: 31915373
PLoS One. 2016 May 13;11(5):e0155676
pubmed: 27175998
Nature. 2019 May;569(7756):418-422
pubmed: 31068698
Nature. 2020 Jan;577(7790):405-409
pubmed: 31775156
CSH Protoc. 2007 Feb 01;2007:pdb.prot4594
pubmed: 21357017
Nat Biotechnol. 2018 Aug;36(7):597-605
pubmed: 29969440
Circ Res. 2019 Aug 2;125(4):398-410
pubmed: 31221018
Nature. 2014 Jun 12;510(7504):273-7
pubmed: 24776797
EMBO J. 2015 Mar 12;34(6):710-38
pubmed: 25712211
Nat Biotechnol. 2015 May;33(5):495-502
pubmed: 25867923
Cell. 2016 Sep 8;166(6):1386-1396
pubmed: 27610565

Auteurs

Christine M Poch (CM)

Medical Department I, Cardiology, Angiology, Pneumology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.

Kylie S Foo (KS)

Department of Cell and Molecular Biology, Karolinska Institutet, Stockholm, Sweden.
Department of Medicine, Karolinska Institutet, Huddinge, Sweden.

Maria Teresa De Angelis (MT)

Medical Department I, Cardiology, Angiology, Pneumology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.
Institute of Regenerative Medicine in Cardiology, Technical University of Munich, Munich, Germany.

Karin Jennbacken (K)

Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.

Gianluca Santamaria (G)

Medical Department I, Cardiology, Angiology, Pneumology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.
Institute of Regenerative Medicine in Cardiology, Technical University of Munich, Munich, Germany.

Andrea Bähr (A)

Medical Department I, Cardiology, Angiology, Pneumology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.

Qing-Dong Wang (QD)

Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.

Franziska Reiter (F)

Medical Department I, Cardiology, Angiology, Pneumology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.

Nadja Hornaschewitz (N)

Medical Department I, Cardiology, Angiology, Pneumology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.

Dorota Zawada (D)

Medical Department I, Cardiology, Angiology, Pneumology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.
Institute of Regenerative Medicine in Cardiology, Technical University of Munich, Munich, Germany.

Tarik Bozoglu (T)

Medical Department I, Cardiology, Angiology, Pneumology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.

Ilaria My (I)

Medical Department I, Cardiology, Angiology, Pneumology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.

Anna Meier (A)

Medical Department I, Cardiology, Angiology, Pneumology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.
Institute of Regenerative Medicine in Cardiology, Technical University of Munich, Munich, Germany.

Tatjana Dorn (T)

Medical Department I, Cardiology, Angiology, Pneumology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.
Institute of Regenerative Medicine in Cardiology, Technical University of Munich, Munich, Germany.

Simon Hege (S)

Medical Department I, Cardiology, Angiology, Pneumology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.

Miia L Lehtinen (ML)

Department of Medicine, Karolinska Institutet, Huddinge, Sweden.

Yat Long Tsoi (YL)

Department of Cell and Molecular Biology, Karolinska Institutet, Stockholm, Sweden.

Daniel Hovdal (D)

Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.

Johan Hyllner (J)

Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Division of Biotechnology, IFM, Linköping University, Linköping, Sweden.

Sascha Schwarz (S)

Center for Applied Tissue Engineering and Regenerative Medicine (CANTER), Munich University of Applied Sciences, Munich, Germany.

Stefanie Sudhop (S)

Center for Applied Tissue Engineering and Regenerative Medicine (CANTER), Munich University of Applied Sciences, Munich, Germany.

Victoria Jurisch (V)

Medical Department I, Cardiology, Angiology, Pneumology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.

Marcella Sini (M)

Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.

Mick D Fellows (MD)

Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.

Matthew Cummings (M)

Western Michigan School of Medicine, Kalamazoo, MI, USA.

Jonathan Clarke (J)

Procella Therapeutics, Stockholm, Sweden.

Ricardo Baptista (R)

Procella Therapeutics, Stockholm, Sweden.

Elif Eroglu (E)

Department of Cell and Molecular Biology, Karolinska Institutet, Stockholm, Sweden.

Eckhard Wolf (E)

Chair for Molecular Animal Breeding and Biotechnology, Gene Center and Department of Veterinary Sciences, LMU Munich, Munich, Germany.

Nikolai Klymiuk (N)

Medical Department I, Cardiology, Angiology, Pneumology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.
DZHK (German Centre of Cardiovascular Research), Munich Heart Alliance, Munich, Germany.

Kun Lu (K)

Walter-Brendel-Centre of Experimental Medicine, University Hospital, LMU Munich, Munich, Germany.

Roland Tomasi (R)

Walter-Brendel-Centre of Experimental Medicine, University Hospital, LMU Munich, Munich, Germany.

Andreas Dendorfer (A)

DZHK (German Centre of Cardiovascular Research), Munich Heart Alliance, Munich, Germany.
Walter-Brendel-Centre of Experimental Medicine, University Hospital, LMU Munich, Munich, Germany.

Marco Gaspari (M)

Department of Experimental and Clinical Medicine, University of Magna Grecia, Catanzaro, Italy.

Elvira Parrotta (E)

Department of Experimental and Clinical Medicine, University of Magna Grecia, Catanzaro, Italy.

Giovanni Cuda (G)

Department of Experimental and Clinical Medicine, University of Magna Grecia, Catanzaro, Italy.

Markus Krane (M)

DZHK (German Centre of Cardiovascular Research), Munich Heart Alliance, Munich, Germany.
Department of Cardiovascular Surgery, INSURE, German Heart Center Munich, Technical University of Munich, Munich, Germany.

Daniel Sinnecker (D)

Medical Department I, Cardiology, Angiology, Pneumology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.
DZHK (German Centre of Cardiovascular Research), Munich Heart Alliance, Munich, Germany.

Petra Hoppmann (P)

Medical Department I, Cardiology, Angiology, Pneumology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.

Christian Kupatt (C)

Medical Department I, Cardiology, Angiology, Pneumology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany. Christian.Kupatt@tum.de.
DZHK (German Centre of Cardiovascular Research), Munich Heart Alliance, Munich, Germany. Christian.Kupatt@tum.de.

Regina Fritsche-Danielson (R)

Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden. Regina.Fritsche-Danielson@astrazenca.com.

Alessandra Moretti (A)

Medical Department I, Cardiology, Angiology, Pneumology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany. amoretti@mytum.de.
Institute of Regenerative Medicine in Cardiology, Technical University of Munich, Munich, Germany. amoretti@mytum.de.
DZHK (German Centre of Cardiovascular Research), Munich Heart Alliance, Munich, Germany. amoretti@mytum.de.

Kenneth R Chien (KR)

Department of Cell and Molecular Biology, Karolinska Institutet, Stockholm, Sweden. kenneth.chien@ki.se.
Department of Medicine, Karolinska Institutet, Huddinge, Sweden. kenneth.chien@ki.se.

Karl-Ludwig Laugwitz (KL)

Medical Department I, Cardiology, Angiology, Pneumology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany. KL.Laugwitz@mri.tum.de.
DZHK (German Centre of Cardiovascular Research), Munich Heart Alliance, Munich, Germany. KL.Laugwitz@mri.tum.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH